Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

• Status: Unknown status
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Collaborator: Kyongbo Pharmaceutical
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• living liver transplantation recipients

Exclusion Criteria:

• preoperative renal dysfunction

• dual living donor liver transplantation

• severe cerebral artery disease

• severe cardio-pulmonary disease